Tickernomics

10y

Historical Returns*:

SPY

27.80%

-28.08%

CANF

SPY

32.66%

-87.90%

CANF

SPY

108.59%

-95.58%

CANF

SPY

302.52%

-99.70%

CANF

*Assumes dividends reinvested

Market Stats:

Market Capitalization($MM)

Enterprise Value($MM)

Daily Volume(MM)

2776.94

2772.21

0.20

Valuation Metrics:

Price/Earnings Ratio

Price/Sales Ratio

Price/Book Value

FCF Yield(%)

Dividend Yield(%)

EV/EBITDA

-375.82

3922.24

1120.19

-74.07

0.00

-338.65

Profitability Stats:

Operating Margin %(ttm)

Gross Profit %(ttm)

EBITDA Margin %(ttm)

-1295.57

100.00

-1295.25

Shareholder Value Creation:

Cost of Capital %(est)

ROIC %(ttm)

ROCE %(ttm)

Beta

9.1408

-312.64

-111.02

1.31

Other Earnings and Cash Flow Stats:

Can-Fite BioPharma Ltd. ( CANF ) Net Income TTM ($MM) is -7.70

Can-Fite BioPharma Ltd. ( CANF ) Operating Income TTM ($MM) is -8.01

Can-Fite BioPharma Ltd. ( CANF ) Owners' Earnings Annual ($MM) is 0.00

Can-Fite BioPharma Ltd. ( CANF ) Current Price to Owners' Earnings ratio is 0.00

Can-Fite BioPharma Ltd. ( CANF ) EBITDA TTM ($MM) is -8.00

Can-Fite BioPharma Ltd. ( CANF ) EBITDA Margin is -1295.25%

Capital Allocation:

Can-Fite BioPharma Ltd. ( CANF ) has paid 0.00 dividends per share and bought back -596.132567 million shares in the past 12 months

Can-Fite BioPharma Ltd. ( CANF ) has increased its debt by 0.0 million USD in the last 12 months

Capital Structure:

Can-Fite BioPharma Ltd. ( CANF ) Interest-bearing Debt ($MM) as of last quarter is 0

Can-Fite BioPharma Ltd. ( CANF ) Annual Working Capital Investments ($MM) are -1

Can-Fite BioPharma Ltd. ( CANF ) Book Value ($MM) as of last quarter is 2

Can-Fite BioPharma Ltd. ( CANF ) Debt/Capital as of last quarter is 0%

Other Balance Sheet Stats:

Can-Fite BioPharma Ltd. ( CANF ) has 4 million in cash on hand as of last quarter

Can-Fite BioPharma Ltd. ( CANF ) has 1 million of liabilities due within 12 months, and long term debt 0 as of last quarter

Can-Fite BioPharma Ltd. ( CANF ) has 1821 common shares outstanding as of last quarter

Can-Fite BioPharma Ltd. ( CANF ) has 0 million USD of preferred stock value

Academic Scores:

Can-Fite BioPharma Ltd. ( CANF ) Altman Z-Score is 441.85 as of last quarter

Can-Fite BioPharma Ltd. ( CANF ) Piotroski Score is 2.00 as of last quarter

Corporate Governance:

Can-Fite BioPharma Ltd. ( CANF ) largest shareholder is Avion Wealth owning 100 shares at 0.00 ($MM) value

(an insider) shares of Can-Fite BioPharma Ltd. ( CANF ) for the amount of $ on

0.00% of Can-Fite BioPharma Ltd. ( CANF ) is held by insiders, and 8.02% is held by institutions

Can-Fite BioPharma Ltd. ( CANF ) went public on 2012-11-06

About Can-Fite BioPharma Ltd. ( CANF ) :

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.